Edition:
United States

Nevro Corp (NVRO.N)

NVRO.N on New York Stock Exchange

89.85USD
12:01pm EDT
Change (% chg)

$-0.91 (-1.00%)
Prev Close
$90.76
Open
$91.38
Day's High
$91.38
Day's Low
$89.70
Volume
14,256
Avg. Vol
77,626
52-wk High
$97.54
52-wk Low
$65.35

Chart for

About

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic... (more)

Overall

Beta: -0.51
Market Cap(Mil.): $2,708.01
Shares Outstanding(Mil.): 29.84
Dividend: --
Yield (%): --

Financials

  NVRO.N Industry Sector
P/E (TTM): -- 35.59 33.60
EPS (TTM): -1.25 -- --
ROI: -9.35 14.13 13.19
ROE: -14.72 16.91 15.00

BRIEF-Nevro Corp Says CEO Rami Elghandour's FY 2017 Total Compensation Was $13.2 Mln

* NEVRO CORP SAYS CEO RAMI ELGHANDOUR'S FY 2017 TOTAL COMPENSATION WAS $13.2 MLN VS $11.5 MLN IN FY 2016 - SEC FILING Source text: [https://bit.ly/2GEJ7Jw] Further company coverage:

Apr 06 2018

BRIEF-Nevro Qtrly Loss Per Share $0.15

* NEVRO REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES 2018 OUTLOOK

Feb 22 2018

BRIEF-Nevro Receives FDA Approval For Senza II

* NEVRO RECEIVES FDA APPROVAL FOR SENZA II SPINAL CORD STIMULATION SYSTEM DELIVERING HF10 THERAPY Source text for Eikon: Further company coverage:

Jan 08 2018

BRIEF-Nevro Sees Q4 Revenue $97.4 Million To $97.9 Million

* NEVRO ANNOUNCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FISCAL YEAR 2017 REVENUE

Jan 08 2018

BRIEF-Nevro reports third quarter 2017 financial results

* Nevro Corp - qtrly net loss per share, basic and diluted $0.21‍​ Source text for Eikon: Further company coverage:

Nov 06 2017

Earnings vs. Estimates